Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 3,201–3,300 of 10,906
Chambers, C., Samji, H., Cooper, C., Costiniuk, C. T., Janjua, N. Z., Kroch, A. E., Arbess, G., Benoit, A. C., Buchan, S. A., Chung, H., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003405 · Cited by 22
Khalid, K., Padda, J., Khedr, A., Ismail, D., Zubair, U., Al-Ewaidat, O. A., Padda, S., Cooper, A. C., & Jean-Charles, G. (2021) · Cureus · doi:10.7759/cureus.16197 · Cited by 34
Vaccines against COVID-19: Priority to mRNA-Based Formulations
Pascolo, S. (2021) · Cells · doi:10.3390/cells10102716 · Cited by 26
Capuano, R., Altieri, M., Conte, M., Bisecco, A., d’Ambrosio, A., Donnarumma, G., Grimaldi, E., Coppola, N., Medici, N., Galdiero, M., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11296-4 · Cited by 23
Cohn, E., Chimowitz, M., Long, T. G., Varma, J. K., & Chokshi, D. A. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(22)00196-7 · Cited by 24
Advances in Engineering Circular RNA Vaccines
Zhang, Z., Fu, Y., Ju, X., Zhang, F., Zhang, P., & He, M. (2024) · Pathogens · doi:10.3390/pathogens13080692 · Cited by 28
COVID-19 Vaccine: Between Myth and Truth
Piccaluga, P. P., Guardo, A. D., Lagni, A., Lotti, V., Diani, E., Navari, M., & Gibellini, D. (2022) · Vaccines · doi:10.3390/vaccines10030349 · Cited by 23
Barmettler, S., DiGiacomo, D. V., Yang, N. J., Lam, T., Naranbhai, V., Dighe, A. S., Burke, K. E., Blumenthal, K. G., Ling, M. F., Hesterberg, P. E., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.03.017 · Cited by 23
Vinh, D. C., Gouin, J., Cruz-Santiago, D., Canac‐Marquis, M., Bernier, S., Bobeuf, F., Sengupta, A., Brassard, J.-P., Guerra, A., Dziarmaga, R., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00012-5 · Cited by 31
Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics
Jiao, X., He, X., Qin, S., Yin, X., Song, T., Duan, X., Shi, H., Jiang, S., Zhang, Y., & Song, X. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1992 · Cited by 31
No apparent association between mRNA COVID-19 vaccination and venous thromboembolism
Nicholson, M. C., Goubran, H. A., Chan, N., & Siegal, D. M. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100970 · Cited by 22
Theodore, D., Branche, A. R., Zhang, L., Graciaa, D. S., Choudhary, M., Hatlen, T. J., Osman, R., Babu, T. M., Robinson, S. T., Gilbert, P. B., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.23349 · Cited by 31
Self-citationTorabi, F., Bedston, S., Lowthian, E., Akbari, A., Owen, R. K., Bradley, D., Agrawal, U., Collins, P. W., Fry, R. J., Griffiths, L. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20118-6 · Cited by 28
Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study
Dauriat, G., Beaumont, L., Nguyen, L. B. L., Renaud-Picard, B., Penhouet, M., Coiffard, B., Salpin, M., Demant, X., Raymond, C. S., Carlier, N., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00502-2022 · Cited by 22
Haynes, B. F., Wiehe, K. J., Alam, S. M., Weissman, D., & Saunders, K. O. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000820 · Cited by 23
Addressing COVID-19 vaccine hesitancy
Kassianos, G. C., Puig‐Barberà, J., Dinse, H., Teufel, M., Türeci, Ö., & Pather, S. (2022) · Drugs in Context · doi:10.7573/dic.2021-12-3 · Cited by 24
Biosecurity risks associated with vaccine platform technologies
Sandbrink, J. B., & Koblentz, G. D. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.02.023 · Cited by 31
Head, J. R., Andrejko, K. L., & Remais, J. V. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100133 · Cited by 25
Alveolar Nitric Oxide as a Biomarker of COVID-19 Lung Sequelae: A Pivotal Study
Cameli, P., Bargagli, E., Bergantini, L., d’Alessandro, M., Giugno, B., Gentili, F., & Sestini, P. (2021) · Antioxidants · doi:10.3390/antiox10091350 · Cited by 23
Hemmi, T., Ainai, A., Hashiguchi, T., Tobiume, M., Kanno, T., Iwata‐Yoshikawa, N., Iida, S., Sato, Y., Miyamoto, S., Ueno, A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.049 · Cited by 25
Magro, F., Nuzzo, A., Abreu, C., Libânio, D., Rodríguez–Lago, I., Pawlak, K. M., Hollenbach, M., Brouwer, W. P., & Siau, K. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12115 · Cited by 21
Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/z4x7t · Cited by 22
Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging
Lemdani, K., Marlin, R., Mayet, C., Perkov, V., Pascal, Q., Ripoll, M., Relouzat, F., Dhooge, N., Bossevot, L., Dereuddre‐Bosquet, N., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00900-5 · Cited by 32
Effects of COVID-19 vaccination on FDG-PET/CT imaging: A literature review
Minamimoto, R., & Kiyomatsu, T. (2021) · Global Health & Medicine · doi:10.35772/ghm.2021.01076 · Cited by 22
COVID-19 vaccination and frailty in older adults
Chen, L. (2021) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2021.104487 · Cited by 22
Gui, Y., Li, X., Li, J., Shen, M., Zhang, M., Cao, Y., Xu, H., Li, H., Cheng, J., Pan, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104586 · Cited by 23
Choi, H. K., Zhang, Y., & Dalbeth, N. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00804-5 · Cited by 24
Lund, L. C., Støvring, H., Pottegård, A., Andersen, M. T., & Hallas, J. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.02.012 · Cited by 26
Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases
Razavi, R., Kegel, M., Muscat-Rivera, J., Weissman, D., & Melamed, J. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101566 · Cited by 32
Polypept(o)ides – Origins, synthesis, applications and future directions
Bauer, T. A., Simić, L., Guyse, J. F. R. V., Duro‐Castaño, A., Nebot, V. J., & Barz, M. (2024) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2024.101889 · Cited by 29
Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Winckelmann, A. A., Bollerup, S., Mikkelsen, L. S., Sørensen, A.-L., Feng, S., Fahnøe, U., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103519 · Cited by 28
Hirotsu, Y., Amemiya, K., Sugiura, H., Shinohara, M., Takatori, M., Mochizuki, H., & Omata, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722766 · Cited by 22
Dang, F., Bai, L., Dong, J., Hu, X., Wang, J., Paulo, J. A., Xiong, Y., Liang, X., Sun, Y., Chen, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh7668 · Cited by 25
Wu, X., Li, W., Rong, H., Pan, J., Zhang, X., Hu, Q., Shi, Z., Zhang, X., & Cui, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c03075 · Cited by 24
Gazitt, T., Eviatar, T., Shear, J., Meidan, R., Furer, V., Feld, J., Haddad, A., Elias, M., Hijazi, N., Stein, N., et al. (2023) · Vaccines · doi:10.3390/vaccines11020476 · Cited by 24
Top, K. A., Chen, R. T., Levy, O., Ozonoff, A., Carleton, B., Crawford, N. W., Creech, C. B., Kochhar, S., Poland, G. A., Gutu, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac407 · Cited by 23
Self-citationGonzález, S. M., Siddik, A. B., & Su, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.612807 · Cited by 23
Influence of COVID-19 vaccines on endocrine system
Zhao, Y. H., & Wu, X. (2022) · Endocrine · doi:10.1007/s12020-022-03119-3 · Cited by 23
Miyara, M., Saichi, M., Sterlin, D., Anna, F., Marot, S., Mathian, A., Atif, M., Quentric, P., Mohr, A., Claër, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.790334 · Cited by 26
Simader, E., Tobudic, S., Mandl, P., Haslacher, H., Perkmann, T., Nothnagl, T., Sautner, J., Radner, H., Winkler, F., Burgmann, H., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221347 · Cited by 23
Singh, V., Obregon-Perko, V., Lapp, S. A., Horner, A. M., Brooks, A. D., Macoy, L., Hussaini, L., Lu, A., Gibson, T., Silvestri, G., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155145 · Cited by 22
Rao, R. P., Musante, C. J., & Allen, R. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00269-6 · Cited by 24
van Helmond, N., Brobyn, T. L., LaRiccia, P. J., Cafaro, T., Hunter, K. M., Roy, S., Bandomer, B., Ng, K. Q., Goldstein, H., Mitrev, L. V., et al. (2022) · Nutrients · doi:10.3390/nu15010180 · Cited by 22
Brown, A., Shah, S., Dluzewski, S., et al. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.04.010 · Cited by 22
Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
Naruse, H., Ito, H., Izawa, H., Sarai, M., Ishii, J., Sakaguchi, E., Murakami, R., Ando, T., Fujigaki, H., & Saito, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235498 · Cited by 23
Sekizawa, A., Hashimoto, K., Kobayashi, S., Kozono, S., Kobayashi, T., Kawamura, Y., Kimata, M., Fujita, N., Ono, Y., Obuchi, Y., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.963393 · Cited by 21
Dewan, S. M. R., & Islam, M. R. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104961 · Cited by 22
Babu, T. M., Feldstein, L. R., Saydah, S., Acker, Z., Boisvert, C. L., Briggs‐Hagen, M., Carone, M., Casto, A. M., Cox, S. N., Ehmen, B., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071446 · Cited by 26
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 25
Lei, S., Li, J., Zhu, M., Zhou, W., Fu, X., Wu, S., Chen, X., Zhang, J., Duan, X., Wang, W., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c18153 · Cited by 25
COVID-19 Vaccination in Patients with Chronic Liver Disease
Schinas, G., Polyzou, E., Mitropetrou, F., Pazionis, A., Gogos, C. A., Triantos, C. K., & Akinosoglou, K. (2022) · Viruses · doi:10.3390/v14122778 · Cited by 23
Cao, L., Yu, Y.-F., Li, Z., Zhong, N., Wang, G.-R., Xiao, Y., Liu, B., Wu, Q., Feng, C., & Bu, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02590-6 · Cited by 31
van der Toorn, W., Oh, D., Bourquain, D. R., Michel, J., Krause, E., Nitsche, A., & von Kleist, M. (2021) · Patterns · doi:10.1016/j.patter.2021.100262 · Cited by 23
Wallace, M. M., Rosenblum, H. G., Moulia, D., Broder, K. R., Shimabukuro, T. T., Taylor, C. A., Havers, F. P., Meyer, S. A., Dooling, K. L., Oliver, S. E., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.037 · Cited by 21
Acquired aplastic anemia following SARS‐CoV ‐2 vaccination
Röth, A., Bertram, S., Schroeder, T. A., Haverkamp, T., Voigt, S., Holtkamp, C., Klump, H., Wormann, B. J., Reinhardt, H. C., & Alashkar, F. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13788 · Cited by 22
Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV
Bessen, C., Plaza‐Sirvent, C., Simsek, A., Bhat, J., Marheinecke, C. S., Urlaub, D., Bonowitz, P., Buße, S., Schumann, S., Blanco, E. V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049070 · Cited by 24
COVID-19 Vaccine Acceptance among Liver Transplant Recipients
Costantino, A., Invernizzi, F., Centorrino, E., Vecchi, M. L., Lampertico, P., & Donato, M. F. (2021) · Vaccines · doi:10.3390/vaccines9111314 · Cited by 22
Nanostructures for the Prevention, Diagnosis, and Treatment of SARS-CoV-2: A Review
Kiremitler, N. B., Kemerli, M. Z., Kayacı, N., Karagöz, S., Pekdemir, S., Sarp, G., Sanduvaç, S., Önses, M. S., & Yılmaz, E. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c00181 · Cited by 21
COVID-19 clinical presentation, management, and epidemiology: a concise compendium
Maison, D. P., Tasissa, H., Deitchman, A. N., Peluso, M. J., Deng, Y., Miller, F. D., Henrich, T. J., & Gerschenson, M. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1498445 · Cited by 35
The clinical progress and challenges of mRNA vaccines
Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1894 · Cited by 30
Cao, H., Mai, J., Zhou, Z. P., Li, Z., Duan, R. C., Watt, J., Chen, Z., Bandara, R. A., Li, M., Ahn, S. K., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00723-0 · Cited by 23
Zhang, Y., Li, D., Shen, Y., Li, S., Lu, S., & Zheng, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161507 · Cited by 29
Sedegah, M., Porter, C. K., Goguet, E., Ganeshan, H. D., Belmonte, M., Huang, J., Belmonte, A. D., Inoue, S., Acheampong, N., Malloy, A. M. W., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276241 · Cited by 24
Güven, D. C., Şahin, T. K., Akın, S., & Uckun, F. M. (2022) · The Oncologist · doi:10.1093/oncolo/oyac032 · Cited by 24
Jilich, D., Skrzat‐Klapaczyńska, A., Fleischhans, L., Bursa, D., Antoniak, S., Balayan, T., Begovać, J., Cicic, A., Dragović, G., Goekengin, D., et al. (2021) · HIV Medicine · doi:10.1111/hiv.13194 · Cited by 21
Peptide‐Based Inhibitors for SARS‐CoV‐2 and SARS‐CoV
Panchal, D., Kataria, J., Patel, K., Crowe, K. M., Pai, V., Azizogli, A., Kadian, N., Sanyal, S., Roy, A., Dodd‐o, J., et al. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100104 · Cited by 23
Vyhmeister, R. H., Enestvedt, C. K., VanSandt, M., et al. (2021) · Liver Transplantation · doi:10.1002/lt.26097 · Cited by 21
A Public Health Ethics Framework for Populations with Limited English Proficiency
Chipman, S. A., Meagher, K. M., & Barwise, A. K. (2023) · The American Journal of Bioethics · doi:10.1080/15265161.2023.2224263 · Cited by 27
Fan, Q., Shi, J., Yang, Y., Tang, G., Jiang, M., Li, J. J., Tang, J., Li, L., Wen, X., Zhang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31693-7 · Cited by 20
Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis
Wang, T. K. M., & Klein, A. L. (2022) · Current Cardiology Reports · doi:10.1007/s11886-021-01621-0 · Cited by 24
Lodhi, N., Singh, R., Rajput, S., & Saquib, Q. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168660 · Cited by 22
Schuler, C. F., IV, Gherasim, C., O’Shea, K. J., Manthei, D. M., Chen, J., Zettel, C., Troost, J. P., Kennedy, A. A., Tai, A. W., Giacherio, D. A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00087-21 · Cited by 22
The COVID-19 Vaccine: Why the Hesitancy?
Grossman, V. A. (2021) · Journal of Radiology Nursing · doi:10.1016/j.jradnu.2021.02.011 · Cited by 25
Hibino, M., Uryu, K., Takeda, T., Kunimatsu, Y., Shiotsu, S., Uchino, J., Hirai, S., Yamada, T., Okada, A., Hasegawa, Y., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.05.015 · Cited by 22
Gaborit, B., Fernandes, S., Loubet, P., Ninove, L., Dutour, A., Cariou, B., Coupaye, M., Clément, K., Czernichow, S., Carette, C., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155412 · Cited by 24
Gemmati, D., Longo, G., Gallo, I., Silva, J. A., Secchiero, P., Zauli, G., Hanau, S., Passaro, A., Pellegatti, P., Pizzicotti, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1028081 · Cited by 24
Challenges and Issues of Anti-SARS-CoV-2 Vaccines
Blumental, S., & Debré, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.664179 · Cited by 24
Alghamdi, A., Ibrahim, A. A. M., Alraey, M. A., Alkazemi, A., Alghamdi, I., & Alwarafi, G. (2021) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/1ufxsztr6m · Cited by 21
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Zhu, C., Pang, S., Liu, J., & Duan, Q. (2024) · Drugs · doi:10.1007/s40265-024-02013-8 · Cited by 28
Hao, Q., Long, Y., Yang, Y., Deng, Y., Ding, Z., Yang, L., Shu, Y., & Xu, H. (2024) · Vaccines · doi:10.3390/vaccines12070717 · Cited by 27
Higher sensitivity monitoring of reactions to COVID-19 vaccination using smartwatches
Guan, G., Mofaz, M., Qian, G. L., Patalon, T., Shmueli, E., Yamin, D., & Brandeau, M. L. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00683-w · Cited by 25
Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults
Bartley, J. M., Cadar, A. N., & Martin, D. E. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1909617 · Cited by 23
Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
Qiao, Y., Wotring, J. W., Zhang, C. J., Jiang, X., Xiao, L., Watt, A., Gattis, D., Scandalis, E., Freier, S. M., Zheng, Y., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281281 · Cited by 21
Utilizing Biologics in Drug Desensitization
Yang, B. C., & Castells, M. (2022) · Current Allergy and Asthma Reports · doi:10.1007/s11882-022-01052-z · Cited by 22
Murray, S. M., Barbanti, M. C., Campbell, C., Brown, A., Chen, L., Dhanapal, J., Tseu, B., Pervaiz, O., Peters, L., Springett, S., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18312 · Cited by 23
Shuvaev, V. V., Tam, Y. K., Lee, B. W., Myerson, J. W., Herbst, D. A., Kiseleva, R. Y., Glassman, P. M., Parhiz, H., Alameh, M., Pardi, N., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409266122 · Cited by 28
“The success of nucleoside - modified mRNA in COVID - 19 vaccines given to billions of people ( 21 , 22 ), FDA - approved siRNA in ONPATTRO ® to treat hereditary transthyretin - mediated amyloidosis ( 6 , 22 – 27 ) and the results of multitudes of clinical and animal studies demonstrate that lipid…”
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study
Gordon, J. K., Showalter, K., Wu, Y., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00416-1 · Cited by 21
Liu, X., Wang, S., Sun, Y., Liao, Y., Jiang, G., Sun, B., Yu, J., & Zhao, D. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105638 · Cited by 27
History of primary-series and booster vaccination and protection against Omicron reinfection
Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0761 · Cited by 30
COVID‐19 vaccine in patients with Dravet syndrome: Observations and real‐world experiences
Hood, V. L., Berg, A. T., Knupp, K. G., Koh, S., Laux, L., Meskis, M. A., Ali, Q. Z., Perry, M. S., Scheffer, I. E., Sullivan, J. E., et al. (2022) · Epilepsia · doi:10.1111/epi.17250 · Cited by 20
Coulon, P.-G. A., Prakash, S., Dhanushkodi, N. R., Srivastava, R., Zayou, L., Tifrea, D. F., Edwards, R. A., Figueroa, C. J., Schubl, S. D., Hsieh, L. L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343716 · Cited by 21
Noor, R. (2021) · Current Clinical Microbiology Reports · doi:10.1007/s40588-021-00172-w · Cited by 23
Living with HIV and Getting Vaccinated: A Narrative Review
VITO, A. D., Colpani, A., Trunfio, M., Fiore, V., Moi, G., Fois, M., Leoni, N., Ruiu, S., Babudieri, S., Calcagno, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11050896 · Cited by 23
Martínez‐Baz, I., Trobajo‐Sanmartín, C., Miqueleiz, A., Casado, I., Navascués, A., Burgui, C., Ezpeleta, C., Castilla, J., Guevara, M., & the Working Group for the Study of COVID-19 in Navarra (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.5.2200337 · Cited by 29
Vollenberg, R., Tepasse, P.-R., Kühn, J. E., Hennies, M., Strauss, M., Rennebaum, F., Schomacher, T., Boeckel, G., Lorentzen, E. U., Bokemeyer, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10010171 · Cited by 26
Wu, J., Ma, M., Miao, Y., Ye, B., Li, Q., Tarimo, C. S., Wang, M., Gu, J., Wei, W., Zhao, L., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.796467 · Cited by 25
A Review of the Current Status of Clinical Management of COVID-19 in the Elderly
Li, Q., & Zhao, C. (2021) · Medical Science Monitor · doi:10.12659/msm.930278 · Cited by 25
Papayanni, P. G., Chasiotis, D., Koukoulias, K., Georgakopoulou, A., Iatrou, A., Gavriilaki, E., Giannaki, C., Bitzani, M., Geka, E., Tasioudis, P., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab371 · Cited by 25
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.